Emad Ibrahim, MD — Redlands, California

Emad Ibrahim, MD is a clinical research site located in Redlands, California, United States 92373.

Crixeo Clinical Trials Trust Score: 22/100 (FAILING). This profile has not yet been claimed by the site owner.

Emad Ibrahim, MD has participated in 24 clinical trials with 10 currently active.

Therapeutic areas: Advanced Non-Small Cell Lung Cancer, Melanoma, Melanoma Stage III.

Sponsors: Regeneron Pharmaceuticals, Nektar Therapeutics, HUYABIO International, LLC..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Redlands

Browse all research sites in California · View every site in Redlands

• University of Redlands
• Loma Linda University
• Redlands Community Hospital
• VA Loma Linda Healthcare System Ambulatory Care System
• Anderson Clinical Research
• Retina Consultants of Southern California
• Research Site
• Clinical Research Site
• Pfizer Investigational Site
• California Eye Specialists Medical Group
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 22/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Emad Ibrahim, MD?

Emad Ibrahim, MD has a Crixeo Trust Score of 22/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Emad Ibrahim, MD conducted?

Emad Ibrahim, MD has 24 clinical trials on record, with 10 currently active. Their work covers Advanced Non-Small Cell Lung Cancer, Melanoma, Melanoma Stage III.

Is Emad Ibrahim, MD accredited by Crixeo Clinical Trials?

Emad Ibrahim, MD has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Emad Ibrahim, MD?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.